Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Oncotarget. 2010 Dec;1(8):729-33.

A beta version of life: p110β takes center stage.

Author information

  • 1Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, USA.

Abstract

The PI3K pathway is frequently activated in tumors, most commonly through p110α mutation or PTEN deletion. In contrast to p110α, p110β is oncogenic when over-expressed in the wild-type state, suggesting that its regulation by p85 is different than that of p110α. In this perspective, we summarize recent data concerning the regulation of p110β, which shows that wild-type p110β acts like an oncogenic mutant of p110α. We also discuss the significance of this altered regulation in tumor models of PTEN deletion, as well as the potential implications of the unique p110β regulation on GPCR-driven tumorigenesis.

PMID:
21321382
[PubMed - indexed for MEDLINE]
PMCID:
PMC3157740
Free PMC Article

Images from this publication.See all images (1)Free text

Figure 1:
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Impact Journals, LLC Icon for PubMed Central
    Loading ...
    Write to the Help Desk